

# Determinants of specific RNA interference-mediated silencing of human $\beta$ -globin alleles differing by a single nucleotide polymorphism

Derek M. Dykxhoorn\*, Lisa D. Schlehuber\*<sup>†</sup>, Irving M. London<sup>†\*§</sup>, and Judy Lieberman\*

\*CBR Institute for Biomedical Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115; <sup>†</sup>Department of Biology and <sup>‡</sup>Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139

Contributed by Irving M. London, February 16, 2006

A single nucleotide polymorphism (SNP) in the sickle  $\beta$ -globin gene ( $\beta^S$ ) leads to sickle cell anemia. Sickling increases sharply with deoxy sickle Hb concentration and decreases with increasing fetal  $\gamma$ -globin concentration. Measures that decrease sickle Hb concentration should have an antisickling effect. RNA interference (RNAi) uses small interfering (si)RNAs for sequence-specific gene silencing. A  $\beta^S$  siRNA with position 10 of the guide strand designed to align with the targeted  $\beta^S$  SNP specifically silences  $\beta^S$  gene expression without affecting the expression of the  $\gamma$ -globin or normal  $\beta$ -globin ( $\beta^A$ ) genes. Silencing is increased by altering the 5' end of the siRNA antisense (guide) strand to enhance its binding to the RNA-induced silencing complex (RISC). Specific  $\beta^S$  silencing was demonstrated by using a luciferase reporter and full-length  $\beta^S$  cDNA transfected into HeLa cells and mouse erythroleukemia cells, where it was expressed in the context of the endogenous  $\beta$ -globin gene promoter and the locus control region enhancers. When this strategy was used to target  $\beta^E$ , silencing was not limited to the mutant gene but also targeted the normal  $\beta^A$  gene. siRNAs, mismatched with their target at position 10, guided mRNA cleavage in all cases except when two bulky purines were aligned. The specific silencing of the  $\beta^S$ -globin gene, as compared with  $\beta^E$ , as well as studies of silencing SNP mutants in other diseases, indicates that siRNAs developed to target a disease-causing SNP will be specific if the mutant residue is a pyrimidine and the normal residue is a purine.

sickle cell anemia | specificity of silencing | hemoglobin E | hemoglobin S

Sickle cell anemia (SCA) results from a single nucleotide substitution in codon 6 (GAG→GTG) of the Hb  $\beta$ -chain gene ( $\beta^S$ ). The Glu→Val substitution produces a Hb variant (HbS) that polymerizes upon deoxygenation to produce long rigid fibers that distort red blood cell (RBC) shape. Sickled RBCs have reduced flexibility that impairs their transit through the microvasculature and leads to vasoocclusion, localized hypoxia, painful crises, and organ damage. The sickled RBCs are also prone to hemolysis with resulting anemia. The intracellular concentration and the polymerization of deoxyHbS are the critical pathogenic determinants of SCA (1, 2). Other Hbs, such as HbA or HbC may permit or promote the polymerization of deoxyHbS, or as with HbF or HbA<sub>2</sub>, may inhibit the polymerization and have an antisickling effect (2). A determinant of SCA severity is the relative abundance of  $\gamma$  and  $\beta^S$ , with elevated levels of fetal HbF ( $\alpha_2\gamma_2$ ) mitigating disease severity. Hydroxyurea (HU) treatment, which increases  $\gamma$ -gene expression, decreases sickle cell crises (3). Similarly, the disease is ameliorated in mouse models of SCA when gene therapy is used to increase the intraerythrocytic concentration of a modified  $\beta^A$  mutated in position 87<sup>Thr→Gln</sup>, a key residue for the antisickling properties of HbF (4).

An alternate therapeutic approach, which we present here, is to decrease the intracellular concentration of HbS by specifically silencing the  $\beta^S$  gene without diminishing the expression of the  $\gamma$  or the normal  $\beta^A$  gene. In recent years, RNA interference

(RNAi) has emerged as a powerful approach for silencing gene expression. RNAi leads to sequence-specific gene silencing in response to small interfering (si)RNAs that guide the degradation of homologous mRNAs (5). One of the siRNA strands (the guide strand) becomes incorporated into the RNA-induced silencing complex (RISC) to direct target mRNA cleavage. The choice of strands that enter RISC is determined by the relative thermodynamic stability of each of the 5' ends; the strand that is energetically favored for unwinding predominates in RISC (6).

siRNAs with incomplete homology to their target mRNA sequence can also silence gene expression. However, the rules that govern which partially homologous target mRNAs are efficiently silenced by any small interfering (si)RNAs are still uncertain. The central region of the siRNA:mRNA interaction site is thought to be critical for silencing (7). Homology at the site of mRNA cleavage (between positions 10 and 11 from the 5' end of the siRNA guide strand) is considered essential for efficient silencing by mRNA degradation but may not be required for the less efficient silencing by inhibition of translation (8–10).


The ability to silence specifically an allele with a disease-causing SNP is desirable not only for SCA, but also for other conditions resulting from a mutant SNP. SNP-selective targeting has already been shown to silence an oncogenic ras (K-RAS<sup>V12</sup>) and a spinocerebellar ataxia gene allele (ataxin-3) (11, 12). Here we investigate SNP-selective targeting of disease-causing alleles of human  $\beta$ -globin. To maximize the potential specificity of silencing,  $\beta$  allele-specific siRNAs were designed so that the SNP was aligned with position 10 of the guide strand. These siRNAs were analyzed by using an allele-specific luciferase reporter. The  $\beta^S$  siRNA specifically silenced the  $\beta^S$  gene, without inhibiting the expression of the normal  $\beta^A$  or  $\gamma$ -globin genes. By altering the thermodynamic properties of the 5' end of the guide strand, silencing could be substantially increased. Despite the high specificity of the  $\beta^S$  siRNA, the corresponding  $\beta^A$  siRNA not only silenced  $\beta^A$  but also silenced the  $\beta^S$  reporter and cDNA expression construct, targeting them for degradation. A further examination of different combinations of nucleotides at the mismatched siRNA:mRNA interaction site demonstrated that central mismatches consisting of pyrimidine:pyrimidine or pyrimidine:purine residues maintained a significant level of silencing by mRNA cleavage. However, introducing two bulky mismatched purines at position 10 abrogated silencing. The same observation was made with siRNAs designed to silence another disease-causing allele ( $\beta^E$ ), which has a codon 26 SNP and produces HbE that is unstable under conditions of oxidative stress and elevated body temperature (13). These findings sug-

Conflict of interest statement: No conflicts declared.

Abbreviations: CFP, cyan fluorescent protein; HbS, sickle hemoglobin; RNAi, RNA interference; siRNA, small interfering RNA; RISC, RNA-induced silencing complex; SCA, sickle cell anemia; YFP, yellow fluorescent protein.

<sup>§</sup>To whom correspondence should be addressed. E-mail: imlondon@mit.edu.

© 2006 by The National Academy of Sciences of the USA



**Fig. 1.** Allele-specific silencing of  $\beta^S$ . (A) *Renilla* luciferase reporter plasmids into which the target  $\beta^A$  and  $\beta^S$  sequences were cloned. (B) The  $\beta^A$  and  $\beta^S$  siRNA sequences were designed with the SNP aligned with position 10 of the guide strand. (C) Transfection of  $\beta^A$  and  $\beta^S$  siRNAs induces allele-specific silencing of the luciferase reporter constructs. The fold repression was determined by the degree of silencing of the *Renilla* luciferase-targeting construct relative to the firefly luciferase control after background subtraction of the GFP control siRNA-treated samples. (D) Sequences of  $\beta^S$  siRNAs destabilized at the 5' terminus of the guide strand. Similar destabilized siRNAs were made for the  $\beta^A$  siRNA. (E) Destabilization of the  $\beta^S$  siRNAs increased the efficacy of silencing but retained the specificity of silencing. (F) The destabilized  $\beta^A$  siRNAs showed enhanced silencing of the  $\beta^A$  target but also showed significant silencing of the  $\beta^S$  reporter. For both sets of siRNAs, restoring the base pair interaction at the 5' terminus eliminated silencing.

gest that mismatches at the mRNA cleavage site involving pyrimidines can be accommodated within the catalytic site of the RISC endonuclease Ago2 and lead to mRNA degradation, despite the lack of a base-paired interaction at the active site. Although earlier studies have examined the position of mismatches on the specificity of silencing, this study shows that the nucleotide composition of the mismatch determines the specificity of the silencing reaction (14).


## Results

Using RNAi as a potential therapeutic agent for SNP  $\beta$ -hemoglobinopathies requires siRNAs to discriminate between  $\beta$ -globin alleles. For SCA, the siRNA needs to silence  $\beta^S$  and have little or no effect on the expression of the  $\gamma$  and  $\beta^A$  genes. Because  $\beta^A$  and  $\beta^S$  differ by only one nucleotide, the most rigorous test of specificity would be to determine whether the  $\beta^S$  siRNA would affect  $\beta^A$  expression. Specific silencing of  $\beta^S$  is particularly important if it is done in conjunction with expression of  $\beta^A$  (4). A 50-nt target sequence from either  $\beta^S$  or  $\beta^A$  containing the region surrounding the SNP was cloned into the 3' UTR of the *Renilla* luciferase expression vector pTK-RL (8) (Fig. 1A). These expression plasmids were cotransfected with  $\beta^S$ ,  $\beta^A$ , or control siRNA and the firefly luciferase control vector (Fig. 1B). The SNP was aligned with position 10 of each siRNA guide strand. The  $\beta^S$  siRNA silenced the  $\beta^S$  reporter target  $\approx 2.5$ -fold with only minimal effects on  $\beta^A$  expression (Fig. 1C). However, the overall silencing was low. To improve silencing, the siRNA was altered at the 5' terminus of the

guide strand to promote the preferential uptake of this strand into the RISC. Replacing the C at position 19 of the sense strand with a U changes the 5' terminal base pair of the guide strand of the siRNA from the stable G:C pairing to the non-Watson-Crick G:U pairing (Fig. 1D). The  $\beta^S$  siRNA containing the G:U base pair [ $\beta^S$ (G:U)] dramatically improved silencing of the reporter construct to  $\approx 9$ -fold compared with the nonspecific control siRNA, without sacrificing specificity (Fig. 1E). Similarly, incorporating a G:G mismatch at the 5' end of the guide strand by replacing the C residue at position 19 of the target strand with a G, producing a frayed or forked siRNA [ $\beta^S$ (G:G)], repressed expression of the  $\beta^S$  target construct  $\approx 7$ -fold and maintained specificity. When the base pairing of the 5' end of the guide strand was restored by modifying both siRNA strands [ $\beta^S$ (C:G)] silencing was minimal (1.2-fold) and reduced compared with the original siRNA. None of the modified  $\beta^S$  siRNAs appreciably targeted the  $\beta^A$  reporter. Therefore, allele-specific silencing of  $\beta^S$  can be achieved, and the efficacy of silencing can be increased by destabilizing base-pairing at the 5' end of the guide strand.

Modifications to the 5' end of the guide strand of the  $\beta^A$  siRNA also enhanced  $\beta^A$  silencing (Fig. 1F). However, in contrast to the specificity of the  $\beta^S$  siRNAs, the highly active modified  $\beta^A$  siRNAs also silenced the  $\beta^S$  target by as much as  $\approx 4$ -fold. These two targeting reactions differ only in the mismatched nucleotides at the site of RISC-mediated endonuclease cleavage, with an A:A mismatch between the  $\beta^S$  siRNA and the  $\beta^A$  mRNA and a U:U mismatch between the  $\beta^A$  siRNA and the






**Fig. 4.** Targeted silencing of  $\beta$ -globin mRNA and protein. (A)  $\beta^S$ (G:U) siRNA silenced  $\beta^S$  mRNA but showed no appreciable targeting of  $\beta^A$  mRNA as determined by RT-PCR and quantitative RT-PCR. The percent expression of the target is given relative to cells transfected with control GFP siRNA. The corresponding  $\beta^A$ (G:U) siRNA effectively silenced  $\beta^A$  mRNA but also efficiently silenced  $\beta^S$  mRNA expression. (B) Similarly, the  $\beta^S$ (G:U) siRNA silenced  $\beta^S$  globin expression, as determined by a lack of  $\beta^S$ -GFP fusion protein in transfected HeLa cells, but had no effect on the expression of  $\beta^A$ -globin ( $\beta^A$ -CFP). The  $\beta^A$ (G:U) siRNA effectively silenced  $\beta^A$ -globin, as well as  $\beta^S$ -globin, expression. dsRed expression was used as a transfection control. (C)  $\beta^S$ (G:U) siRNA silences  $\beta^S$  in MEL cells stably expressing  $\beta^S$  from the human globin promoter and locus control region, compared with control siRNA-treated cells.

decreased (>5-fold) in treated cells compared with control siRNA-treated cells (Fig. 4C).

Because the severity of SCA is reduced by fetal ( $\gamma$ ) globin gene expression, a therapeutic siRNA designed to reduce  $\beta^S$  expression should not reduce fetal  $\gamma$ -globin gene expression. The  $\gamma$ -globin gene differs from  $\beta^A$  or  $\beta^S$  in the 19-nt targeted sequence by 7 or 8 nucleotide mismatches, respectively. It is therefore unlikely that either the  $\beta^A$  or  $\beta^S$  siRNA would silence  $\gamma$ -globin expression (Fig. 5A). To verify this conjecture, a corresponding 50-bp region of the  $\gamma$ -globin gene was cloned into the *Renilla* luciferase expression vector and tested for silencing when co-transfected with  $\beta^S$ (G:U),  $\beta^A$ (G:U), or control siRNA. None of these siRNAs silenced  $\gamma$ -globin (Fig. 5B). However, an siRNA designed to target the corresponding  $\gamma$  sequence silenced  $\gamma$  but not  $\beta^A$  or  $\beta^S$ . These findings were corroborated by RT-PCR and real-time PCR analysis of HeLa cells transfected with a  $\gamma$ -globin expression plasmid (Fig. 5C and D).  $\gamma$ -globin mRNA was efficiently targeted by the  $\gamma$  siRNA but not by the  $\beta^A$  or  $\beta^S$  siRNAs.  $\gamma$ -globin mRNA was even somewhat higher in the  $\beta^A$ - and  $\beta^S$ -treated samples. Therefore,  $\beta^S$  siRNA does not interfere with fetal globin gene expression.

## Discussion

A key factor that makes RNAi a powerful gene silencing tool and potential therapeutic is its specificity (5). Early studies demonstrated the possibility of specifically silencing a mutant allele differing by only a SNP and leaving the normal allele unaffected



**Fig. 5.**  $\beta^S$  siRNA does not reduce fetal  $\gamma$ -globin expression. (A) Schematic of the  $\gamma$  sequence targeted by the siRNAs against  $\beta^S$  and  $\beta^A$ . (B) The  $\beta^S$  and  $\beta^A$  siRNAs do not repress  $\gamma$  expression of a luciferase reporter construct containing a 50-nt region of the  $\gamma$ -globin gene corresponding to the homologous region encoded by the  $\beta^S$  and  $\beta^A$  reporter constructs. Likewise, an siRNA against  $\gamma$ -globin failed to target  $\beta^S$  and  $\beta^A$ . (C and D) Expression of full length  $\gamma$  from the CMV promoter is silenced by a  $\gamma$  siRNA, but not by the  $\beta^S$ (G:U) and  $\beta^A$ (G:U) siRNAs, as shown by RT-PCR (C) and quantified by real-time RT-PCR (D). All values are relative to GFP siRNA-treated cells.

(10–12). However, it is now known that siRNAs also silence some targets with incomplete homology (5, 15). The central region of the siRNA between position 5 and 11 is the most sensitive to mismatches in the mRNA sequence, in particular positions 9, 10, and 11, which surround the mRNA cleavage site (5, 10, 16). The goal of this study was to design an allele-specific siRNA targeting the SNP of sickle  $\beta^S$  without affecting normal  $\beta^A$  or fetal  $\gamma$ -globin gene expression. By aligning the siRNA so that the SNP paired with position 10 of the siRNA guide strand, we were able to design an siRNA that silenced  $\beta^S$  but left  $\beta^A$  and  $\gamma$ -globin expression intact. This siRNA could be improved by introducing mismatches at the 5' end of the guide strand to favor association of the guide, rather than the sense, strand with the RISC.

Our control  $\beta^A$  siRNAs unexpectedly directed cleavage of the  $\beta^S$  reporter gene and  $\beta^S$  mRNA, despite a mismatch at the critical position of endonuclease cleavage. By examining gene silencing by siRNAs designed to target  $\beta^A$ ,  $\beta^S$ , and another  $\beta$ -globin allele ( $\beta^E$ ) with various siRNA:mRNA mispairings at position 10, we found that an otherwise well matched siRNA can cleave its target mRNA, provided the mismatch is not composed of two bulky purine residues. siRNAs that are fully matched except for mismatched purine:pyrimidine or pyrimidine:pyrimidine residues at position 10 can still efficiently guide mRNA cleavage. This result suggests that the Ago2 catalytic site can accommodate some siRNA:mRNA mismatches, in particular, combinations of mismatches that involve the smaller pyrimidine residues. There are no structural studies of Ago2, but two groups have crystallized the endonuclease domain of a homologous bacterial protein bound to a small siRNA-like duplex (17, 18). Although the 5' end of the siRNA guide strand was well ordered in the crystal and embedded in the bacterial Piwi protein, the region corresponding to position 10 was disordered, suggesting that the active site may allow some flexibility for binding. This observation is consistent with our finding that certain mismatches at the active site still permit significant mRNA cleavage.

Analysis of allele-specific silencing in other disease-causing SNPs supports our conclusion that an siRNA can specifically silence a gene containing an SNP without affecting the normal allele only when there is a purine:purine mismatch of the mutant

allele siRNA and the normal target mRNA (see Table 1, which is published as supporting information on the PNAS web site). RNAi-mediated targeting of K-RAS<sup>V12</sup>, resulting from a G→T transition in codon 12, significantly silenced K-RAS<sup>V12</sup> but not normal K-RAS (12). The K-RAS<sup>V12</sup> siRNA:normal K-RAS mRNA would contain a bulky purine:purine (A:G) mismatch at position 9 relative to the 5' terminus of the guide siRNA strand, supporting the hypothesis that the juxtaposition of these bulky residues would impair silencing of the normal allele. In another example, an siRNA targeting a dominant SNP in SOD1, implicated in amyotrophic lateral sclerosis, showed minimal targeting of the normal allele because of the presence of a G:G mismatch (10). The specificity of silencing was strongest when the mismatch occurred at position 10 of the guide strand. However, the siRNA targeting the normal allele strongly cross-reacted to silence the mutant allele when the mismatch contained two pyrimidine (C:C) residues. In another study, allele-specific targeting was possible for mutant ataxin-3, which contains a G→C substitution immediately 3' to the polyglutamine encoding CAG repeats but not for a disease-causing SNP in Tau (Tau<sup>V337M</sup>, resulting from a G→A transition) (11). The mutant ataxin-3 siRNA that juxtaposed two purine residues (G:G) at position 11 when bound to the normal mRNA did not silence the normal allele. On the other hand, the siRNA designed to target Tau<sup>V337M</sup> significantly inhibited expression of the normal allele. In that case, the mismatch with the normal mRNA consisted of a purine:pyrimidine G:U wobble. The Tau mutant allele could be specifically silenced when an additional mismatch was incorporated into the siRNA. A similar strategy has made it possible to increase the specificity of  $\beta^E$  silencing (data not shown). In yet another example, an siRNA directed against HIV-1 *vif* silenced a variant gene containing a single nucleotide mismatch corresponding to position 9 of the siRNA guide strand (19). Again, this cross-reactivity could be explained by the presence of the non-Watson-Crick U:G pair. Interestingly, adding a methyl group to the U residue, N<sup>3</sup>-methyl-uridine, at position 11 of the siRNA guide strand inhibited silencing. The addition of this relatively small chemical group may have inhibited RNA-RISC interactions (20).

Our findings suggest that not only the position, but also the specific nucleotide combination, at mismatched sites helps determine the specificity of silencing. Significant silencing of the mRNA may occur with any combination of nucleotides that contains a pyrimidine, whether on the siRNA or the mRNA. Therefore, when designing siRNAs for the targeting of disease-causing alleles without impairing the expression of the normal allele, one wants to avoid purine:pyrimidine and pyrimidine:pyrimidine mismatches of the siRNA with the normal target mRNA, if silencing of the normal allele is not desirable. Although this rule should be generalizable to silencing other genes with other disease-related SNPs, how broadly applicable it is remains to be tested. This study, however, suggests that efficient allele-specific silencing of a mutant gene that differs from the normal allele by only a SNP can best be achieved in cases where the mutant residue is a pyrimidine and the normal residue is a purine. In this case, the siRNA targeting the mutant allele would contain a purine residue that would prevent silencing of the normal allele, as exemplified with the siRNA against sickle globin (Figs. 1 and 2). This situation is expected to occur in only one-fourth of cases. In the remaining situations, it may be necessary to add mismatches between the siRNA and mRNA, as was done to silence SNPs in Tau (11) and  $\beta^E$ -globin (data not shown). However, the introduction of additional mismatches may come at the cost of less effective silencing because of reduced homology to the target sequence.

The rules that determine off-target silencing of partially homologous genes by siRNAs or that determine the endogenous targets of microRNAs are still not well defined. Although we

have only investigated mismatches at position 10, it may be that the same principle applies at other sites, namely that a guide strand:mRNA purine:purine mismatch will result in significantly less (or potentially no) silencing compared with a mismatch containing at least one pyrimidine. This rule appears to be the case for nucleotides in the vicinity of the mRNA cleavage site, but it might also apply to the region important for mRNA target recognition, the "seed sequence" from positions 2–7 from the 5' end of the guide strand.

Designing allele-specific siRNAs to target  $\beta^S$  is only a first step toward testing whether RNAi can be harnessed to treat SCA. A key challenge is delivering siRNAs or their precursors into erythroid progenitors *in vivo*. There are two potential strategies: a drug approach in which siRNAs are delivered by a carrier or a gene therapy approach in which viral vectors express short hairpin (sh)RNAs, processed intracellularly into siRNAs. The latter approach has the potential advantage of providing life-long therapy (assuming transduction is efficient and expression is robust and sustained) but has the associated potential risks of insertional oncogenesis. A recent paper has shown that the coexpression of an shRNA against  $\beta^S$  and a  $\gamma$ -globin transgene had therapeutic benefit in human erythrocytes derived from lentivirally transduced hematopoietic stem cells (21). A drug-like siRNA would require repeated treatments and a strategy for efficient systemic delivery into erythroid precursors. Recently some potential approaches for practical systemic siRNA delivery have been described, including targeting siRNAs in a cell-specific manner (22, 23). We are currently investigating both of these approaches in a mouse model of SCA.

Another potential concern in developing RNAi-based therapy for SCA is that silencing  $\beta^S$  expression will lead to unbalanced  $\alpha$  chain expression,  $\alpha$  chain precipitation, and hemolysis. This imbalance might be mitigated if silencing  $\beta$ -globin resulted in compensatory enhanced expression of fetal globin. Alternatively, siRNA-mediated silencing could be done in conjunction with the therapeutic expression of  $\beta^{A87Thr\rightarrow Gln}$ -globin (4) or  $\gamma$ -globin (21) to provide the dual advantages of silencing and replacing the mutant allele with an antisickling form of globin. Because polymerization of deoxyHbS depends on its concentration, a large clinical benefit might be possible with modest panerythroid silencing.

## Materials and Methods

**Expression and Reporter Plasmids.** A 50-nt region of the  $\beta^A$  and  $\beta^S$  genes surrounding codon 6 and of  $\beta^A$  and  $\beta^E$  surrounding codon 26 was cloned downstream of the *Renilla* luciferase reporter gene in pRL-TK (Promega), which had been modified to contain XbaI and ApaI cloning sites in the 3' UTR of the luciferase gene as described (8). The sequences are given in the figures. The  $\beta^A$  and  $\gamma$ -globin cDNAs were from Origene Technologies (Rockville, MD). The  $\beta^S$  variant was obtained by site-directed mutagenesis by using the QuikChange II site-directed mutagenesis kit (Stratagene) with complementary forward and reverse primers (forward primer, 5'-GCACCTGACTCCTGTGGAG-AAGTCTG-3'). These sequences were PCR-amplified by using forward (5'-GGACTCAACTCGAGCAGACACCATGGTG-CACCTGACTCC-3') and reverse (5'-GTGTGGCGACCCGG-GAGTGATACTTGTGGGCCAGGGCATTAGC-3') primers and cloned by using XbaI and ApaI into pECFP-N1 or pEYFP-N1 (Clontech) to express fluorescently tagged fusion proteins.

**siRNAs.** To maximize the specificity of silencing, the globin siRNAs were designed to place the mismatched nucleotide at position 10 relative to the 5' end of the antisense strand. The 5' terminal end of the siRNA guide strand was altered to maximize efficacy of silencing. All siRNAs were synthesized by Dharmma

con Research (Lafayette, CO) with sequences indicated in the figures. The control siRNA against GFP was described in ref. 24.

**Cells.** HeLa and MEL- $\beta^S$  cells were cultured in DMEM supplemented with 10% FCS, 1 mM L-glutamine, 10 mM Hepes, 50  $\mu$ M 2-mercaptoethanol, penicillin, and streptomycin.

**Luciferase Reporter Assay.** HeLa cells, plated at  $2 \times 10^5$  cells per well in 12-well plates 1 day earlier, were cotransfected with 1  $\mu$ g *Renilla* luciferase reporter plasmid, 1  $\mu$ g of firefly luciferase vector (pGL3, Promega) and 200 nM of the indicated siRNA by using Lipofectamine 2000 transfection reagent as per the manufacturer's protocol (Invitrogen). Luciferase activity was assessed by using the Dual-luciferase reporter assay system (Promega) and read on an Autolumat LB953 (Berthold Technologies, Bad Wildbad, Germany).

**RT-PCR.**  $\beta$ -globin expression plasmids (0.5  $\mu$ g) were cotransfected by using Lipofectamine 2000 (Invitrogen) with the indicated siRNA (100 nM) into HeLa cells ( $4 \times 10^5$  cells per well in 6-well plates). Total RNA was extracted 2 days later by using the RNeasy RNA extraction kit (Qiagen, Valencia, CA). First strand cDNA synthesis was performed by using random hexamer primers and Superscript III reverse transcriptase (Invitrogen). Globin gene segments were PCR amplified by using primers:  $\beta^A$  forward, 5'-ATGGTGCATCTGACTCCTGA-3';  $\beta^S$  forward, 5'-ATGGTGCATCTGACTCCTGT-3';  $\beta^A$  and  $\beta^S$  reverse, 5'-TAAAGGCACCGAGCACTTTC-3';  $\gamma$  forward, 5'GGCTACTATCACAAGCCTG-3';  $\gamma$  reverse, 5'-CCTTCTTGCCATGT-

GCCTTG-3'). The QuantumRNA Universal 18S Internal Standard was used as a positive control (Ambion, Austin, TX). Real-time PCR was used to quantify mRNA by using a Bio-Rad iCycler.  $\beta$ -actin was used as an internal control.

**Real-Time RT-PCR.** Real-time RT-PCR was performed with the same primer pairs used above, except that a common  $\beta$ -globin forward primer was used, 5'-ATGGTGCATCTGACTCCTCG-3'. Real-time PCR was performed by using Platinum Taq polymerase (Invitrogen) and a Bio-Rad iCycler. SYBR green (Molecular Probes) was used to detect PCR products. Reactions were performed in 25  $\mu$ l in triplicate by using standard reaction conditions. Standard curves were generated, and the relative amount of mRNA was normalized to 18S mRNA. Specificity was verified by melt curve analysis.

**Microscopy.** Microscopy was performed by using an Axiovert 200M inverted microscope (Zeiss) with YFP, CFP, and Cy3 filters (for dsRed) and analyzed by using SLIDEBOOK V.4.0.1.32 (Intelligent Imaging Innovations, Denver, CO).

We would like to thank Dr. Eric Bouhassira (Albert Einstein College of Medicine, Yeshiva University, New York) for the kind gift of MEL- $\beta^S$  cells and members of the Lieberman laboratory for helpful suggestions and comments. This work was supported by National Institutes of Health Grants AI056900 (to J.L.) and P01 HL 055435-11 (to I.M.L.), and by a fellowship (to L.D.S.) under a National Institutes of Health Training Grant 5 T32 HL007556-19 to Dr. Ronald Nagel (Albert Einstein College of Medicine, Yeshiva University, New York).

1. Stuart, M. J. & Nagel, R. L. (2004) *Lancet* **364**, 1343–1360.
2. Ferrone, F. & Nagel, R. I. (2001) in *Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management*, eds. Steinberg, M. H., Forget, B. G., Higgs, D. R. & Nagel, R. L. (Cambridge Univ. Press, Cambridge, U.K.), pp. 577–610.
3. Charache, S., Dover, G. J., Moyer, M. A. & Moore, J. W. (1987) *Blood* **69**, 109–116.
4. Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., *et al.* (2001) *Science* **294**, 2368–2371.
5. Dykxhoorn, D. M. & Lieberman, J. (2005) *Annu. Rev. Med.* **56**, 401–423.
6. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S. & Khvorovova, A. (2004) *Nat. Biotechnol.* **22**, 326–330.
7. Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W. & Tuschl, T. (2001) *EMBO J.* **20**, 6877–6888.
8. Doench, J. G., Petersen, C. P. & Sharp, P. A. (2003) *Genes Dev.* **17**, 438–442.
9. Saxena, S., Jonsson, Z. O. & Dutta, A. (2003) *J. Biol. Chem.* **278**, 44312–44319.
10. Ding, H., Schwarz, D. S., Keene, A., Affar, E. B., Fenton, L., Xia, X., Shi, Y., Zamore, P. D. & Xu, Z. (2003) *Aging Cell* **2**, 209–217.
11. Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L. & Paulson, H. L. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 7195–7200.
12. Brummelkamp, T. R., Bernards, R. & Agami, R. (2002) *Cancer Cell* **2**, 243–247.
13. Rees, D. C., Styles, L., Vichinsky, E. P., Clegg, J. B. & Weatherall, D. J. (1998) *Ann. N.Y. Acad. Sci.* **850**, 334–343.
14. Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E. & Prydz, H. (2002) *Nucleic Acids Res.* **30**, 1757–1766.
15. Lee, S. K., Dykxhoorn, D. M., Kumar, P., Ranjbar, S., Song, E., Maliszewski, L. E., Francois-Bongarcon, V., Goldfeld, A., Swamy, N. M., Lieberman, J. & Shankar, P. (2005) *Blood* **106**, 818–826.
16. Du, Q., Thonberg, H., Wang, J., Wahlestedt, C. & Liang, Z. (2005) *Nucleic Acids Res.* **33**, 1671–1677.
17. Ma, J. B., Yuan, Y. R., Meister, G., Pei, Y., Tuschl, T. & Patel, D. J. (2005) *Nature* **434**, 666–670.
18. Parker, J. S., Roe, S. M. & Barford, D. (2005) *Nature* **434**, 663–666.
19. Jacque, J. M., Triques, K. & Stevenson, M. (2002) *Nature* **418**, 435–438.
20. Chiu, Y. L. & Rana, T. M. (2003) *RNA* **9**, 1034–1048.
21. Samakoglu, S., Lisowski, L., Budak-Alpdogan, T., Usachenko, Y., Acuto, S., Di Marzo, R., Maggio, A., Zhu, P., Tisdale, J. F., Riviere, I. & Sadelain, M. (2006) *Nat. Biotechnol.* **24**, 89–94.
22. Song, E., Zhu, P., Lee, S. K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., *et al.* (2005) *Nat. Biotechnol.* **23**, 709–717.
23. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., *et al.* (2004) *Nature* **432**, 173–178.
24. Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J., Lee, S. K., Collman, R. G., Lieberman, J., Shankar, P. & Sharp, P. A. (2002) *Nat. Med.* **8**, 681–686.